Novo Nordisk: 67.8% of CagriSema recipients lost 5% of their weight by week eight
Key Facts
On November 15, Novo Nordisk announced results from two post hoc analyses of the REDEFINE 1 trial, which showed that 67.8% of adults who received CagriSema at a dose of 2.4/2.4 mg had lost at least 5% of their weight by week eight. The response-timing analysis included 1,367 early responders and 649 late responders. Average weight loss at week eight was 7.8% in the first group, compared with 3.4% in the second. The company said people respond to treatment over different timeframes and that it continues to study the trial data in greater depth. It stressed, however, that the analysis was exploratory and hypothesis-generating, and that its findings do not provide a basis for changing clinical decisions.
REDEFINE 1 ran for 68 weeks and included 3,417 adults with obesity or overweight and at least one comorbidity, but without type 2 diabetes. In an analysis of outcomes by response timing, 73.3% of early responders achieved weight loss of at least 20% at week 68, compared with 37.2% of late responders. Women were more likely to be among the early responders: 71.8% of that group, compared with 59.5% of late responders. These figures show the difference in outcomes between the two analysis groups during the treatment period. The company said the findings were observed during the treatment period and remain exploratory.
The second post hoc analysis examined physical function: 73.1% of CagriSema recipients reported a meaningful improvement at week 68, compared with 49.1% on placebo. This estimate assumes participants adhered to treatment. The analysis of psychosocial function also showed a meaningful improvement among 69.0% of recipients, compared with 42.1% in the placebo group. These measures add functional dimensions to the assessment of weight outcomes, but were reported as part of post hoc analyses of the trial. The company did not present these findings as a basis for changing clinical decisions.
On tolerability, adverse events in REDEFINE 1 were primarily gastrointestinal. Nausea was reported by 55% of CagriSema recipients, compared with 12.6% on placebo, while vomiting was reported by 26.1% versus 4.1%. Adverse events led to treatment discontinuation for 5.9% of participants in the CagriSema group, compared with 3.5% in the placebo group. These figures put the analysis results in the context of treatment discontinuation and the adverse events recorded in the trial. Novo is studying the drug, a combination of cagrilintide and semaglutide, for weight management in adults.
The results of the two analyses came a day after the company announced results from REDEFINE 9, the first Phase 3 trial to test CagriSema for weight management at doses below 2.4/2.4 mg. In an estimate assuming participants remained on treatment, estimated weight loss at week 68 was 20.7% and 21.0% for the 1.7/1.7 and 1.0/1.0 mg doses, respectively, compared with 2.0% on placebo. The treatment-regimen estimate, which accounts for the effect of discontinuation or use of rescue intervention for weight management, showed estimated weight loss of 19.4% and 18.6% for the two doses, compared with 4.6% on placebo. The difference between the figures reflects the methodology used to account for participants who discontinued treatment or used rescue intervention.
On the regulatory front, Novo said it submitted an application to the U.S. Food and Drug Administration in December 2025 for CagriSema at a dose of 2.4/2.4 mg for weight management, with a decision expected in the fourth quarter of 2026. It said the drug is not approved in the United States. In market reaction, Investing.com reported that the company’s shares rose 2.4% on November 16 following the presentation of additional REDEFINE 1 analyses. The Wall Street Journal’s coverage said the shares rose before the market opened following trial results and European approval of a hemophilia treatment. These reports do not attribute the share move to CagriSema data alone.